Diabetic peripheral neuropathy, the progressive damage to peripheral nerves caused by chronic high blood sugar, affects roughly half of people with diabetes over their lifetime and sets the stage for a cascade of devastating outcomes. When sensation in the feet is lost, minor injuries go unnoticed, wounds fail to heal, ulcers develop, and infections can burrow into bone. In the worst cases, the resulting osteomyelitis or the fragmented, inflamed joints of Charcot neuroarthropathy end in amputation. The condition is also a marker of systemic vulnerability; patients with neuropathic foot complications face substantially elevated mortality. With GLP-1 receptor agonists now prescribed to millions of people worldwide, understanding how these drugs influence the neuropathic foot has become a pressing clinical question.

Led by Fady Tawfik of Howard University College of Medicine, with colleagues at Texas A&M University College of Medicine and the University of Maryland School of Medicine, the research team turned to the TriNetX US Collaborative Network, a federated database aggregating de-identified electronic health records from dozens of American healthcare organizations. They identified adults with a diagnosis of type 2 diabetes mellitus and diabetic neuropathy, unspecified, coded under ICD-10-CM as E11.40, who had newly initiated either a GLP-1 receptor agonist or a DPP-4 inhibitor. Both drug classes act on the incretin system—the hormonal axis that amplifies insulin secretion after meals—but through different mechanisms. GLP-1 receptor agonists mimic the glucagon-like peptide-1 hormone directly and resist enzymatic breakdown, while DPP-4 inhibitors block the enzyme dipeptidyl peptidase-4 that normally degrades endogenous GLP-1, modestly prolonging its action.

Because patients prescribed these drugs often differ systematically in age, weight, kidney function, and overall disease burden, naive comparisons would be misleading. The investigators therefore applied 1:1 propensity score matching, a statistical technique that pairs each GLP-1 receptor agonist user with a DPP-4 inhibitor user who shares a similar demographic and clinical profile, including comorbidities and concomitant medications. After exclusions and matching, the final cohorts contained 19,770 patients per group, well balanced on the measured baseline covariates. The researchers then tracked five outcomes over one and two years: diabetic foot ulcer, lower-extremity amputation, osteomyelitis of the foot or ankle, Charcot neuroarthropathy, and all-cause mortality. Time-to-event analyses employed Kaplan–Meier curves and Cox proportional hazards models, with a Bonferroni correction setting the threshold for statistical significance at p less than 0.01 to guard against false positives across multiple comparisons.

The headline result concerned foot ulcers, the most common entry point into the cycle of neuropathic foot disease. At one year, 2.2 percent of GLP-1 receptor agonist users had been diagnosed with a diabetic foot ulcer compared with 2.7 percent of DPP-4 inhibitor users, corresponding to a hazard ratio of 0.813 with a 95 percent confidence interval of 0.716 to 0.922. In practical terms, the GLP-1 group experienced roughly a 19 percent relative reduction in ulcer risk over the first year. All-cause mortality was also lower in the GLP-1 group, a finding the authors interpreted as hypothesis-generating rather than definitive, given the observational design and the possibility of residual confounding.

Not every result favored the newer drugs. The apparent survival advantage and ulcer reduction came alongside an unexpected signal: Charcot neuroarthropathy occurred in 0.3 percent of GLP-1 users versus 0.2 percent of DPP-4 inhibitor users, a hazard ratio of 1.993 with a confidence interval of 1.297 to 3.064, meaning nearly a doubling of risk that reached statistical significance. By contrast, rates of lower-extremity amputation, at 0.5 percent in both groups, and foot or ankle osteomyelitis, at 0.4 percent in both groups, were indistinguishable, with hazard ratios crossing unity comfortably.

Why might a drug that reduces foot ulcers simultaneously raise the risk of Charcot neuroarthropathy? The authors and prior literature point to several plausible mechanisms. Charcot neuroarthropathy is widely understood as an “imperfect storm”: an injury to an insensate foot triggers an exaggerated inflammatory response in which osteoclast-driven bone resorption outpaces repair, producing fractures, joint disorganization, and the classic rocker-bottom deformity. Rapid improvements in glycemic control are a recognized trigger for acute neuropathic and Charcot events, a phenomenon related to treatment-induced neuropathy of diabetes, in which abruptly normalized blood sugar provokes acute painful neuropathy and arterio-venous shunting in nerve and bone microvasculature. GLP-1 receptor agonists are potent glucose-lowering agents, and their initiation in patients with poorly controlled diabetes could reproduce this dynamic, destabilizing bone in a foot already numbed by neuropathy.

Counteracting mechanisms may explain the ulcer benefit. Experimental work has shown that GLP-1 receptor signaling exerts neuroprotective and anti-inflammatory effects on peripheral nerves. Studies in diabetic rodent models demonstrated that the GLP-1 receptor agonist exendin-4 improved experimental polyneuropathy, and research in streptozotocin-induced diabetic rats found that GLP-1 receptor activation ameliorated nerve dysfunction by damping the p38 MAPK and nuclear factor kappa-B inflammatory pathways. Human imaging studies have reported that GLP-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy, and a recent meta-analysis in the Journal of Neurochemistry concluded that the class shows favorable effects on diabetic peripheral neuropathy overall. Independent of nerves, GLP-1 signaling appears to accelerate wound repair: liraglutide facilitated keratinocyte migration and healing through the PI3K/Akt pathway, exendin-4 accelerated diabetic wound closure in surgical models, and recent reviews describe GLP-1 receptor agonists as emerging modulators of inflammation and angiogenesis in chronic wounds, partly through vascular endothelial growth factor signaling. Fewer ulcers and better healing would naturally translate into fewer deep infections, which is consistent with the similar osteomyelitis rates despite different ulcer trajectories.

The findings land in a contentious literature. Previous emulated target trials have produced divergent results: one published in Diabetes Care comparing GLP-1 receptor agonists with SGLT2 inhibitors found differential amputation outcomes between classes, while another in Annals of Internal Medicine examined sodium-glucose cotransporter-2 inhibitors against GLP-1 receptor agonists for diabetic foot disease with mixed conclusions. A pharmacological database study in Diabetes, Obesity and Metabolism examined incretin-based therapy and foot ulcer risk broadly, and a nationwide observational study in Diabetes Care reported that GLP-1 receptor agonists were associated with reduced mortality after diabetic foot ulcers. The new Journal of Neurology analysis is among the first to focus specifically on patients who already have neuropathy—the population at highest risk—and the first in this context to surface Charcot neuroarthropathy as a comparative safety signal between incretin classes.

The authors are careful about causality. As a retrospective cohort study of administrative coding data, the analysis cannot prove that GLP-1 receptor agonists caused fewer ulcers or more Charcot feet. Unmeasured confounding remains possible despite propensity matching; physicians may preferentially prescribe GLP-1 receptor agonists to patients deemed healthier or more adherent, a phenomenon known as channeling bias that has been documented in glucose-lowering drug studies. Coding of Charcot neuroarthropathy is uncommon and inconsistently applied, and although the doubling of risk reached the corrected significance threshold, the absolute numbers were small—roughly three additional cases per thousand patients per year. The modest absolute reduction in ulcers, about five additional ulcer-free patients per thousand at one year, likewise requires context.

Even so, the study carries practical messages. For the growing population of patients with type 2 diabetes and established neuropathy, GLP-1 receptor agonist therapy appears, on balance, favorable for foot health, reinforcing their established cardiovascular and mortality benefits rather than undermining them. But clinicians initiating these potent glucose-lowering agents in patients with preexisting nerve damage should remain alert to the rare possibility of rapid glycemic improvement triggering neuropathic worsening or Charcot joint destruction. The authors emphasize that vigilant foot surveillance during therapy, including prompt evaluation of warmth, swelling, or deformity in an insensate foot, is warranted. Charcot neuroarthropathy caught early can be treated with offloading and immobilization before irreversible deformity sets in; caught late, it is a leading cause of amputation. As GLP-1 receptor agonists continue their meteoric rise from injectable diabetes drugs to near-universal metabolic therapy, this study is a reminder that even celebrated drugs demand close study of their effects on the body’s most vulnerable territories—and that the diabetic foot, more than most, keeps score.

The original DASH diet, introduced in the mid-1990s, was designed to address hypertension through a diet rich in fruits, vegetables, and low-fat dairy products, while limiting saturated fats and cholesterol. Over the past decades, the DASH diet has been extensively validated as a means to reduce high blood pressure, but its potential effects on glycemic control, particularly in individuals with type 2 diabetes, had not been thoroughly examined in a controlled clinical setting. The DASH4D variant was therefore conceptualized and empirically tested to fill this critical gap.

In designing DASH4D, the Johns Hopkins team strategically reduced carbohydrate intake while increasing unsaturated fat consumption, optimizing the macronutrient profile to better suit individuals with insulin resistance and impaired glucose metabolism. Furthermore, the diet was adjusted to lower potassium content to ensure safety and applicability for diabetes patients who may be concurrently affected by chronic kidney disease, a common comorbidity that complicates dietary recommendations.

The clinical study, published in the prestigious journal Nature Medicine on August 5, rigorously evaluated the effectiveness of the DASH4D diet through a crossover trial involving 89 participants with type 2 diabetes. Each participant consumed the DASH4D diet for half of the 20-week study period and a standard U.S. diet – representative of average American dietary patterns – for the other half. This study utilized continuous glucose monitoring (CGM) technology, permitting real-time, high-resolution assessment of blood glucose fluctuations throughout the intervention.

Analyses demonstrated that adherence to the DASH4D diet elicited a clinically meaningful decrease in average blood glucose levels, with a reduction of approximately 11 mg/dL compared to the standard American diet. Moreover, participants spent an additional 75 minutes per day with glucose levels maintained within the optimal glycemic range, a crucial determinant of reducing diabetes-related complications such as cardiovascular disease and nephropathy. These improvements are particularly notable considering the diets were isocaloric, highlighting the impact of dietary composition over caloric restriction alone.

Importantly, the study observed that participants with initial poor glycemic control, defined by an HbA1c exceeding 8%, experienced more pronounced benefits. In this subgroup, the time spent in the target glucose range increased by an estimated three hours daily when following the DASH4D diet, underscoring the diet’s potential as an impactful therapeutic option for patients with more severe metabolic dysregulation. This finding suggests a possible dose-response relationship between glucose control and dietary prioritization of macronutrient quality.

The trial’s crossover design, wherein participants served as their own controls under varying sodium and diet regimens, enhanced the robustness of the findings by minimizing inter-individual variability and bolstering statistical power despite the relatively modest sample size. Sodium content was manipulated across diet periods to further examine the interplay between sodium intake, hypertension, and glucose regulation, although the primary focus remained on the comparative impacts of DASH4D versus standard dietary intake.

From a mechanistic perspective, the DASH4D diet’s higher unsaturated fat content and reduced carbohydrates may help modulate insulin sensitivity and attenuate postprandial glucose excursions, which are pivotal in mitigating oxidative stress and inflammatory responses that exacerbate diabetic complications. The low saturated fat and cholesterol content also contribute to improved endothelial function, which is often compromised in metabolic syndromes, thereby addressing two critical pathogenic pathways within a single dietary framework.

The research team meticulously prepared all meals for participants in a clinical research setting, cumulatively providing over 40,000 standardized meals to ensure dietary adherence and precise nutrient delivery. This level of control eliminates common confounders inherent to free-living dietary interventions, reinforcing the validity and translational potential of the results. The participant cohort, predominately female (67%) and African American (88%), also highlights the diet’s efficacy in populations disproportionately affected by type 2 diabetes, addressing a vital equity consideration in metabolic disease research.

In addition to the glycemic improvements, the study found that blood glucose variability decreased on the DASH4D diet, a factor increasingly recognized as independently predictive of diabetes-related microvascular complications. Furthermore, the risk of hypoglycemia—a dangerous drop in blood glucose—was not increased on DASH4D relative to the standard diet, suggesting that the diet is both effective and safe when managing glycemic control in the diabetic population.

The compelling outcomes of this trial herald significant implications for public health and clinical practice. Given that approximately 35 million Americans live with type 2 diabetes, and the frequency of co-existing hypertension is alarmingly high due to widespread consumption of unhealthy, processed foods rich in sugars, animal fats, and salt, the DASH4D diet provides a scientifically grounded, sustainable, and culturally sensitive option to better manage these intertwined conditions.

Senior investigator Elizabeth Selvin, PhD, MPH, noted that although the original DASH diet has been recommended for many years for individuals with diabetes due to its blood pressure-lowering benefits, this study provides the first rigorous evidence linking a specifically modified DASH diet to improved glycemic control. Her colleague Michael Fang, PhD, MHS, emphasized the practical aspects of DASH4D, underscoring its design intent to be accessible and realistic for long-term dietary adherence, a critical challenge in nutritional interventions.

Given the potential to reduce the risk of debilitating cardiovascular and renal outcomes, the researchers advocate for the integration of the DASH4D diet into clinical guidelines for type 2 diabetes management. They anticipate that wider adoption could lead to meaningful population health improvements and a decrease in the burden of diabetes-related complications.

This research was supported by substantial funding from the National Institute of Diabetes and Digestive and Kidney Diseases as well as the National Heart, Lung, and Blood Institute. The continuous glucose monitoring devices used in the study were generously provided by Abbott Diabetes Care. The trial is part of a broader initiative to refine lifestyle-based interventions tailored to the needs of metabolic disease sufferers.

In summary, the DASH4D diet stands out as an evidence-based nutritional strategy capable of achieving dual improvements in blood pressure and glycemic control, addressing two of the most critical and co-morbid risk factors for morbidity and mortality in type 2 diabetes. This study not only deepens our understanding of diet-disease interrelationships but also presents a practical, scalable approach that holds promise for transforming diabetes care worldwide.

Subject of Research: Effects of a modified DASH diet on glucose control and blood pressure in adults with type 2 diabetes.

Article Title: DASH4D Diet for Glycemic Control and Glucose Variability in Type 2 Diabetes: A Randomized Crossover Trial

News Publication Date: August 5, 2025

Web References: https://www.nature.com/articles/s41591-025-03823-3

References: Trial publication in Nature Medicine (2025)

Image Credits: Not provided

Keywords: Diabetes, Type 2 Diabetes, DASH Diet, Blood Glucose, Glycemic Control, Hypertension, Clinical Trial, Nutritional Intervention, Continuous Glucose Monitoring, Metabolic Health